Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06195332

Open Vs. Endoscopic Transversus Abdominis Release Trial

This study aims to comparatively evaluate the early and long-term results of open and endoscopic TAR procedure for large midline incisional ventral hernias.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Clinical City Hospital #1 named after N.I. Pirogov

Moscow, Russia

Location status: Recruiting

Location contact

Georgy Ivakhov, Prof

CONTACT

[email protected]

+79264578568

About this study

Minimally invasive (endoscopic) transversus abdominis release (TAR) - new technique for the treatment of patients with large incisional ventral hernia. Term "endoscopic" TAR combines two minimally invasive (laparosopic or extraperitoneal (eTEP) approaches. These techniques have demonstrated significant advantages compared with open TAR in several retrospective studies. There are currently no randomized trials comparing open and endoscopic TAR operations for incisional ventral hernia repair.This study aims to comparatively evaluate the early and long-term results of open and endoscopic TAR procedure for large midline incisional ventral hernias.

The sample size was determined based on a previously conducted retrospective pilot study comparing the results of open and endoscopic TAR procedures for midline incisional ventral hernia repair. The retrospective study included 133 patients with midline incisional ventral hernias who were underwent Rives-Stoppa hernia repair in combination with bilateral posterior component separation with transversus abdominis release via open (open TAR) or endoscopic (eTAR) technique in Moscow City Hospital №1 from January 2018 to December 2022. All patients were included in the study, starting from the moment of endoscopic TAR technique was introduced into the clinic. At the same time, the learning curve for the open TAR had already been reached at that time; more than 20 open TAR interventions were performed in the clinic in 2016-2017. The average hospitalization time in open TAR group was 6.7 ± 2.14 days. In endoscopic TAR group the average hospitalization time after surgery was 5.2 ± 1.65 bed days. After achieving the learning curve (20 operations) for the endoscopic TAR procedure technique average hospitalization period after surgery was 4.8 ± 1.47 days. Thus, a decrease in the duration of hospitalization in endoscopic TAR group after reaching the learning curve was noted by 28.4%. This fact, based on a retrospective pilot study, allows the investigators to assume as a hypothesis for this RCT a reduction in the duration of hospitalization during endoscopic TAR by at least 30% as a guideline for calculating the power of the study. Thus, assuming a Type I error probability α of 0.05 and a Type 2 error probability β of 0.20, it would require a total sample size of 36 patients (18 patients in each group).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • midline incisional hernia
  • defect width from 8 till 12 cm
  • ASA I-III class
  • able to give informed consent
  • elective hernia repair
  • considered eligible for minimally invasive ventral hernia repair

Exclusion criteria

  • primary ventral hernia
  • lateral hernia with/without midline
  • refuse to give informed consent

Treatment and study plan

open TAR

Procedure

Participants will undergo open TAR repair according to the assigned treatment arm.

Other names: open transversus abdominis release

endoscopic TAR

Procedure

Participants will undergo endoscopic TAR repair according to the assigned treatment arm.

Other names: endoscopic transversus abdominis release

Primary outcomes

  1. length of stay after surgery

    Time frame: 30 days after surgery

    From date of operation until discharge

Secondary outcomes

  1. duration of operation

    Time frame: period of operation

    time from beginning to the end of surgery

  2. surgical site occurrences rate

    Time frame: 30 days after surgery

    incidence of all type of wound complications

  3. surgical site infection rate

    Time frame: 30 days after surgery

    incidence of wound infection

  4. rate of postoperative complications

    Time frame: 30 days after surgery

    number of participants with postoperative complications

  5. rate of postoperative complications Clavien 3a and higher

    Time frame: 30 days after surgery

    number of participants with postoperative complications Clavien 3a and higher, evaluated by Clavien-Dindo classification of surgical complications from Dindo et al.

  6. Comprehensive complication index

    Time frame: 30 days after surgery

    Comprehensive complication index will be calculated after verification of all complications and their classification according to Clavien, evaluated by Clavien-Dindo classification of surgical complications from Dindo et al. Minimum (0 points) - best results, maximum (100 points) - worst result (patient death)

Study contacts

Contact information is provided by the study sponsor or research team.

Alexander Sazhin, professor

CONTACT

[email protected]

+79163904180

Georgy Ivakhov, professor

CONTACT

+79262844224

Sponsors and collaborators

Lead sponsor

City Clinical Hospital No.1 named after N.I. Pirogov

Other

Collaborators

  • Pirogov Russian National Research Medical University

Registry information

Official study title

Comparison of Open and Endoscopic Transversus Abdominis Release for Midline Incisional Ventral Hernia - a Randomized Controlled Trial

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jan 8, 2024
Registry last updated
Dec 18, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.